Literature DB >> 17981549

Physiological myocardial hypertrophy: how and why?

Daniele Catalucci1, Michael V G Latronico, Oyvind Ellingsen, Gianluigi Condorelli.   

Abstract

Cardiac hypertrophy is defined by augmentation of ventricular mass as a result of increased cardiomyocyte size, and is the adaptive response of the heart to enhanced hemodynamic loads due to either physiological stimuli (post-natal developmental growth, training, and pregnancy) or pathological states (such as hypertension, valvular insufficiency, etc). The mechanisms leading to hypertrophy during pathological and physiological states are distinct but, in general, evidence indicates that hypertrophy results from the interaction of mechanical forces and neurohormonal factors. Hemodynamic overload creates a mechanical burden on the heart and results in stretch of the myocyte and induction of gene expression of cardiac growth factors. Insulin-like growth factor 1 (IGF1) has recently been shown to be the most important cardiac growth factor involved in physiological hypertrophy. In this review, IGF1 and the pathways it triggers will be discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17981549     DOI: 10.2741/2681

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  42 in total

1.  NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis.

Authors:  Min Zhang; Alison C Brewer; Katrin Schröder; Celio X C Santos; David J Grieve; Minshu Wang; Narayana Anilkumar; Bin Yu; Xuebin Dong; Simon J Walker; Ralf P Brandes; Ajay M Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

Review 2.  Is the 'athlete's heart' arrhythmogenic? Implications for sudden cardiac death.

Authors:  Thomas Rowland
Journal:  Sports Med       Date:  2011-05-01       Impact factor: 11.136

3.  Normal lactational environment restores cardiomyocyte number after uteroplacental insufficiency: implications for the preterm neonate.

Authors:  M Jane Black; Andrew L Siebel; Oksan Gezmish; Karen M Moritz; Mary E Wlodek
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-03-07       Impact factor: 3.619

4.  PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) regulates G-protein-coupled receptor kinase 5 (GRK5)-induced cardiac hypertrophy in vitro.

Authors:  Szu-Tsen Yeh; Cristina M Zambrano; Walter J Koch; Nicole H Purcell
Journal:  J Biol Chem       Date:  2018-04-08       Impact factor: 5.157

5.  Cardiac overexpression of insulin-like growth factor 1 attenuates chronic alcohol intake-induced myocardial contractile dysfunction but not hypertrophy: Roles of Akt, mTOR, GSK3beta, and PTEN.

Authors:  Bingfang Zhang; Subat Turdi; Quan Li; Faye L Lopez; Anna R Eason; Piero Anversa; Jun Ren
Journal:  Free Radic Biol Med       Date:  2010-08-01       Impact factor: 7.376

Review 6.  Cardiac fibroblast: the renaissance cell.

Authors:  Colby A Souders; Stephanie L K Bowers; Troy A Baudino
Journal:  Circ Res       Date:  2009-12-04       Impact factor: 17.367

Review 7.  Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.

Authors:  P H Sugden; S J Fuller; S C Weiss; A Clerk
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

8.  Akt increases sarcoplasmic reticulum Ca2+ cycling by direct phosphorylation of phospholamban at Thr17.

Authors:  Daniele Catalucci; Michael V G Latronico; Marcello Ceci; Francesca Rusconi; Howard S Young; Paolo Gallo; Marco Santonastasi; Alfonso Bellacosa; Joan Heller Brown; Gianluigi Condorelli
Journal:  J Biol Chem       Date:  2009-08-19       Impact factor: 5.157

9.  Neuronal nitric oxide synthase is indispensable for the cardiac adaptive effects of exercise.

Authors:  Steve R Roof; Lifei Tang; Joseph E Ostler; Muthu Periasamy; Sandor Györke; George E Billman; Mark T Ziolo
Journal:  Basic Res Cardiol       Date:  2013-02-04       Impact factor: 17.165

10.  Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure.

Authors:  Cristi L Galindo; Michael A Skinner; Mounir Errami; L Danielle Olson; David A Watson; Jing Li; John F McCormick; Lauren J McIver; Neil M Kumar; Thinh Q Pham; Harold R Garner
Journal:  BMC Physiol       Date:  2009-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.